COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Bringing next-gen cannabinoid therapeutics to cancer patients
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
Subscribe To Our Newsletter & Stay Updated
